News | August 12, 2024
Novo Nordisk's H1 sales increased by 24% in Danish kroner
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Nearly 200 participants from 50 Unani Academia and Council participated
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
GSK and Flagship to jointly fund up to $150 million upfront
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Subscribe To Our Newsletter & Stay Updated
